Table 3 Predictors of remission at 52 weeks of adalimumab treatment (multivariate analysis)
From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
| Factor | Odds ratio (95 % CI) | P value |
|---|---|---|
| CDAI at baseline | 0.993 (0.985–1.000) | 0.0577 |
| Colonic type | 0.207 (0.035–1.230) | 0.0833 |
